Federal Register Notice: FDA has determined the regulatory review period for Johnson & Johnson’s Zubrin (tepoxalin) is 1,887 days because an application has been submitted to the director of Patents and Trademarks, Department of Commerce, for extending a patent which claims that drug product. Zubrin is indicated for controlling pain and inflammation associated with osteoarthritis. To view this notice, click here.
